Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific Inc. (NYSE: TMO) is frequently in the news as the world leader in serving science, with disclosures and press releases covering its activities across life sciences, diagnostics, analytical instruments and pharma services. News about Thermo Fisher often highlights how the company’s technologies and services support customers in accelerating life sciences research, solving analytical challenges, improving laboratory productivity, enhancing diagnostics and enabling the development and manufacture of life‑changing therapies.
Recent Thermo Fisher news includes strategic collaborations, regional investments, product clearances, capital allocation decisions and financing transactions. The company announced a collaboration with NVIDIA to power AI‑based solutions and laboratory automation, pairing its scientific instruments and lab software with NVIDIA’s AI infrastructure to increase automation, accuracy and speed in laboratories. It also reported an expansion of its bioprocessing capabilities in Asia through Bioprocess Design Centers in Incheon, Hyderabad and Singapore, aimed at supporting the region’s biopharmaceutical industry.
Thermo Fisher’s news flow also covers regulatory and clinical milestones, such as 510(k) clearance in the United States for the EXENT System, an automated platform designed as an aid in the diagnosis of multiple myeloma and related disorders. Financial and corporate updates include announcements of euro‑denominated and U.S. dollar‑denominated senior note offerings, a $5 billion share repurchase authorization, quarterly dividends, and agreements and completions related to acquisitions such as Solventum Corporation’s purification and filtration business and Clario Holdings, Inc.
Visitors to this TMO news page can review a stream of these company‑specific developments, from earnings‑related announcements and conference presentations to leadership changes and strategic initiatives disclosed in press releases and SEC‑linked communications.
Thermo Fisher Scientific Inc. (TMO) announced a $3 billion share repurchase authorization, effective immediately and with no expiration date. This new authorization replaces the previous one, which had $500 million remaining. The company's annual revenue stands at approximately $35 billion, emphasizing its position as a leader in serving science. The buyback aims to enhance shareholder value by reducing the number of shares outstanding, which can result in an increase in earnings per share (EPS).
Thermo Fisher Scientific (NYSE: TMO) will have its CEO, Marc N. Casper, present virtually at the JP Morgan 12th Annual U.S. All Stars Conference on September 22, 2021, at 9:00 a.m. EDT. This event showcases the company's commitment to advancing scientific research through innovative solutions. Thermo Fisher, with annual revenues of approximately $35 billion, serves a wide range of scientific needs globally.
Access the webcast via the Investors section of Thermo Fisher's website.
Thermo Fisher Scientific (NYSE: TMO) announced the launch of the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR system. This innovative technology aims to provide accurate and consistent results in just 90 minutes, enhancing applications in oncology and gene therapy. By acquiring Combinati's advanced dPCR technology, Thermo Fisher aims to expedite innovation in cancer research. The system simplifies workflows, reducing hands-on time to five minutes, minimizing user errors, and accelerating genetic analysis processes for biotech and academic institutions.
Thermo Fisher Scientific (NYSE: TMO) will host a virtual Investor Day on September 17, 2021, from 9:00 a.m. to 11:00 a.m. (EDT). The event will include presentations by senior management, followed by a Q&A session. Investors can access the live webcast through the company's website, with a replay available later. Thermo Fisher Scientific, a leader in serving science, reported annual revenues over $30 billion and employs over 80,000 colleagues to support life sciences research and laboratory productivity.
Thermo Fisher Scientific (NYSE: TMO) has secured a $192.5 million contract from the U.S. Department of Defense to boost domestic production of pipette tips, essential for research and diagnostics, including COVID-19 testing. The award includes co-investment in a new, energy-efficient manufacturing facility in North Carolina, set to commence operations by Q3 2023 and complete by Q3 2024. This initiative aims to enhance supply chain resilience and job creation while supporting the company’s net-zero carbon emissions goal by 2050.
Thermo Fisher Scientific has priced an offering of $3.1 billion in senior notes to finance the pending acquisition of PPD, Inc. The offering includes:
- $700 million of 1.750% senior notes due 2028
- $1.2 billion of 2.000% senior notes due 2031
- $1.2 billion of 2.800% senior notes due 2041
Thermo Fisher Scientific (NYSE: TMO) announced it will offer USD-denominated senior notes to fund part of its acquisition of PPD, Inc. This offering is part of a registration statement filed with the SEC. The company emphasizes that the offering does not constitute an offer to sell or solicit notes in jurisdictions where it would be unlawful. The offering aims to meet capital needs for strategic growth while adhering to market conditions. Thermo Fisher has engaged key financial institutions, including Barclays and Morgan Stanley, as joint book-running managers for this offering.
Summary not available.
Thermo Fisher Scientific (NYSE: TMO) has launched a new cGMP plasmid DNA manufacturing facility in Carlsbad, California, addressing the rising demand for plasmid DNA-based therapies and mRNA vaccines. This 67,000-square-foot facility is part of a broader investment strategy aimed at ensuring high-quality materials for gene therapies. The expansion will create over 150 jobs and complements Thermo Fisher's existing infrastructure in various locations. CEO Marc N. Casper emphasized the necessity of this facility for the production of life-saving medicines.
Thermo Fisher Scientific (NYSE:TMO) announced an expansion of its partnership with My Green Lab to enhance sustainability in scientific research. The goal is to obtain the Accountability, Consistency and Transparency (ACT) labeling for its cold temperature storage portfolio by the end of 2021. Over 1,200 additional SKUs are expected to be labeled, thus aiding laboratories in sustainable purchasing. Thermo Fisher offers ENERGY STAR® certified freezers using eco-friendly refrigerants and aims for a 70% reduction in energy consumption compared to conventional alternatives.